Abbott India Limited has submitted its quarterly regulatory certificate to BSE Limited, maintaining compliance with securities regulations for the quarter ended March 31, 2026. The pharmaceutical company filed the mandatory certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.

Regulatory Compliance Certificate

The certificate was submitted on April 8, 2026, by Company Secretary Sangeeta Shetty to the Corporate Relations Department of BSE Limited. The document confirms the company's adherence to regulatory requirements for the Q4FY26 quarter.

Certificate Details and Confirmations

KFin Technologies Limited, serving as Abbott India's Registrar and Transfer Agent, issued the certificate dated April 4, 2026. The certificate provides several key confirmations regarding the handling of securities during the quarter:

• Securities received from depository participants for dematerialization were confirmed to the depositories
• All securities comprised in the certificates have been listed on stock exchanges where earlier issued securities are listed
• Security certificates received for dematerialization were mutilated and cancelled after due verification
• The depositories' names were substituted in the Register of Members as Registered Owner within the stipulated 30-day period

Corporate Structure and Operations

Abbott India Limited operates from its corporate office at Godrej BKC in Mumbai's Bandra-Kurla Complex, while maintaining its registered office at Corporate Park, Sion Trombay Road. The company's operations are supported by KFin Technologies Limited, which operates from Hyderabad with its registered office in Mumbai.

Regulatory Framework

The submission falls under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, which mandates quarterly confirmations regarding the proper handling of dematerialized securities. This regulatory requirement ensures transparency and proper record-keeping in the securities market, protecting investor interests and maintaining market integrity.

Abbott India has announced a strategic partnership with Novo Nordisk India to commercialize Extensor® (semaglutide injection) for people living with type 2 diabetes. This collaboration brings together Novo Nordisk's global GLP-1 leadership and Abbott's strong distribution network to expand access to evidence-based diabetes therapy across India.

Partnership Overview

Under this strategic agreement, Abbott will commercialize Novo Nordisk's semaglutide under the brand name Extensor®, which is a second brand of Ozempic®, the world's most prescribed GLP-1 RA (receptor agonist) molecule. The partnership leverages Abbott's established market presence in India with Novo Nordisk's specialized expertise in diabetes care solutions.

Product Benefits and Clinical Evidence

Extensor® is approved as an adjunct to diet and exercise for adults with type 2 diabetes. The medication offers powerful HbA1c reduction, compelling weight-loss benefits, and proven risk reduction of cardiovascular and kidney events in people with type 2 diabetes. Semaglutide has demonstrated safety and efficacy through 44+ robust clinical trials and 10+ real-world studies, with more than 49 million patient years of use across all semaglutide products globally.

Market Context and Need

India faces one of the world's fastest-growing diabetes burdens, with more than 100 million individuals currently living with diabetes. This number is projected to surge to more than 150 million by 2050—a 50% increase driven by rapid urbanization, aging populations, increasing obesity and lifestyle changes. The country faces a significant care gap, with 43% of individuals with diabetes remaining undiagnosed, limiting opportunities for early intervention.

Leadership Statements

Kartik Rajendran, Managing Director of Abbott India Limited, emphasized that addressing India's diabetes challenge requires continuous innovation and strong partnerships. He noted that Extensor® builds on Abbott's longstanding focus on holistic diabetes management, from medicines to diagnostics and continuous glucose monitoring to diabetes-specific nutrition.

Vikrant Shrotriya, Managing Director of Novo Nordisk India, highlighted that semaglutide represents one of the most significant scientific advancements in diabetes care in recent decades, offering meaningful improvements in metabolic, renal and cardiovascular health. The partnership with Abbott will help make this innovative molecule accessible to a greater number of people living with type 2 diabetes in India.